Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

Cancer research - 15 Oct 2009

Reim Florian, Dombrowski Yvonne, Ritter Cathrin, Buttmann Mathias, Häusler Sebastian, Ossadnik Monika, Krockenberger Mathias, Beier Dagmar, Beier Christoph P, Dietl Johannes, Becker Jürgen C, Hönig Arnd, Wischhusen Jörg

Abstract excerpt

Although trastuzumab (Herceptin) has substantially improved the overall survival of patients with mammary carcinomas, even initially well-responding tumors often become resistant. Because natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is thought to contribu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibody-Dependent Cell Cytotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD24 Antigen

Share to Drug Synergism

Share to Hyaluronan Receptors

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Trastuzumab

Source

Identifiers

PMID: 19826050
DOI: 10.1158/0008-5472.CAN-09-0834

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19826050-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.PMID 19826050Read ↗

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).Semantic proximity Read ↗

miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancerSemantic proximity Read ↗

miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancerSemantic proximity Read ↗

Basal/HER2 breast carcinomasSemantic proximity Read ↗

HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of EvilSemantic proximity Read ↗

Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2‐positive cancer cells and cancer stem cellsSemantic proximity Read ↗

A novel molecular marker of breast cancer stem cells identified by cell-SELEX method.Semantic proximity Read ↗

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Semantic proximity Read ↗

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.Semantic proximity Read ↗

Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.Semantic proximity Read ↗

Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)Semantic proximity Read ↗

Phenotypic and microRNA characterization of the neglected CD24+ cell population in MCF-7 breast cancer 3-dimensional spheroid culture.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.